Neurocrine Biosciences, Inc. announced that CRENESSITY (crinecerfont) is now commercially available in the United States. CRENESSITY was recently approved by the U.S. Food and Drug Administration as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with classic congenital adrenal hyperplasia (CAH).
CRENESITY is exclusively available through PANTHERx Rare, a specialty pharmacy, to centralize and simplify prescription fulfillment. Neurocrine Biosciences is committed to supporting patients in obtaining treatment with CRENESSITY by offering Neurocrine Access Support, a comprehensive assistance program.
The company expects 90% of patients will have a monthly copay of $12 or less, demonstrating efforts to ensure patient access. This commercial launch follows the FDA approval in December 2024, making the first new treatment for classic CAH in 70 years accessible to patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.